



SITC 2017

November 8-12
NATIONAL HARBOR
MARYLAND

Gaylord National Hotel
& Convention Center



Society for Immunotherapy of Cancer

SITC
2017

Reversing the tumor immune escape with Selenium

Claudia Lennicke

Institute of Medical Immunology, Halle, Germany



Society for Immunotherapy of Cancer

#SITC2017

Presenter Disclosure Information

Claudia Lennicke

The following relationships exist related to this presentation:

No Relationships to Disclose

Selenium, in brief

- ✓ an essential trace element


RDI: 30 – 70 µg

- ✓ an „anti-oxidant“ ★


- ✓ cancer therapeutic protential?




Selene,
the goddess of the moon

Selenoprotein	Chromosomal location (number of exons)	Sec location in protein (length of protein)	Selenoprotein structure
15kDa	1p22.3 (5)	93 (162)	
DII	1p32.3 (4)	126 (249)	
DI2	14q31.1 (2)	133 (265)	
DI3	14q32	144 (278)	
★ GPx1	3p21.31 (2)	47 (201)	
★ GPx2	14q23.3 (2)	40 (190)	
★ GPx3	5q33.1 (5)	73 (226)	
★ GPx4	19p13.3 (7)	73 (197)	
★ GPx6	6p22.1 (5)	73 (221)	
H	11q12.1 (4)	44 (122)	
I	2p23.3 (10)	387 (397)	
K	3p21.31 (5)	92 (94)	
M	22q12.2 (5)	48 (145)	
N	1p36.11 (12)	428 (556)	
O	22q13.33 (9)	667 (669)	
★ P	5p12 (4)	59, 300, 318, 330, 345, 352, 367, 369, 376, 378 (381)	
★ R	16p13.3 (4)	95 (116)	
S	15q26.3 (6)	188 (189)	
SPS2	-	60 (448)	
T	3q24 (6)	36 (182)	
★ TR1	12q23.3 (15)	498 (499)	
★ TR2	3q21.2 (16)	655 (656)	
★ TR3	22q11.21 (18)	522 (523)	
V	19q13.13 (6)	273 (346)	
W	19q13.32 (6)	13 (87)	


Selenium, in brief



Selenium, in brief



MSA upregulates MHC class I



Flow cytometry analysis of B16F10 cells exposed to MSA



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany


ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

TIMO
Tumor Immunology
Meets Oncology


DGfI
Deutsche Gesellschaft
für Immunologie e.V.

DFG


MSA upregulates MHC class I



Flow cytometry analysis of B16F10 cells exposed to MSA



MSA upregulates MHC class I



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany


ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

TIMO
Tumor Immunology
Meets Oncology

DGfI
Deutsche Gesellschaft
für Immunologie e.V.





DFG

MSA upregulates MHC class I





Abnormalities of APM components and MHC class I surface antigens are often associated with an immune escape of tumor cells

MSA upregulates MHC class I




B16F10 melanoma cells, treatment 2.5 μ M MSA for 24 hrs, * $p < 0.05$, ** $p < 0.01$ (student's t test)

MSA activates JAK/STAT signaling



MSA is redox active



ROS, reactive oxygen species;
DCF, 2', 7' -dichlorofluorescein

B16F10 melanoma cells, treatment 2.5 μ M MSA
for 24 hrs, * p <0.05, ** p <0.01 (student's t test)



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany


ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

TIMO
Tumor Immunology
Meets Oncology


DGfI
Deutsche Gesellschaft
für Immunologie e.V.

DFG

MSA is redox active



Redox sensitive cysteine residues can be oxidized by ROS



ROS, reactive oxygen species;
DCF, 2', 7' -dichlorofluorescein

B16F10 melanoma cells, treatment 2.5 μM MSA
for 24 hrs, *p < 0.05, **p < 0.01 (student's t test)



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany


ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

TIMO
Tumor Immunology
Meets Oncology


DGfI
Deutsche Gesellschaft
für Immunologie e.V.

DFG

MSA is redox active



Redox sensitive cysteine residues can be oxidized by ROS



➔ Are redox switches involved in the MSA mediated upregulation of MHC class I????



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE


TIMO
Tumor Immunology
Meets Oncology

DGfI
Deutsche Gesellschaft
für Immunologie e.V.


DFG

The iodoTMT technology

- ✓ Identification of redox-modified proteins
- ✓ Identification of redox-modified cysteine residues
- ✓ Multiplex analysis



The MSA redoxome



##Databases: PANTHER, KEGG PATHWAY

##Statistical test method: hypergeometric test / Fisher's exact test

##FDR correction method: Benjamini and Hochberg

Term	No. of proteins	Corrected P-Value
Protein processing in endoplasmic reticulum	9	1,75E-03
Lysosome	9	3,72E-04
Response to elevated platelet cytosolic Ca^{2+}	6	3,85E-03
Detoxification of reactive oxygen species	5	3,50E-04
trans-Golgi network vesicle budding	5	6,87E-03
Golgi associated vesicle biogenesis	4	1,56E-02
Selenocompound metabolism	3	1,73E-02
Calnexin/calreticulin cycle	3	1,39E-02



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany


ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE

TIMO
Tumor Immunology
Meets Oncology

DGfI
Deutsche Gesellschaft
für Immunologie e.V.

DFG

The MSA redoxome



##Databases: PANTHER, KEGG PATHWAY

##Statistical test method: hypergeometric test / Fisher's exact test

##FDR correction method: Benjamini and Hochberg

Term	No. of proteins	Corrected P-Value
Protein processing in endoplasmic reticulum	9	1,75E-03
Lysosome	9	3,72E-04
Response to elevated platelet cytosolic Ca ²⁺	6	3,85E-03
Detoxification of reactive oxygen species	5	3,50E-04
trans-Golgi network vesicle budding	5	6,87E-03
Golgi associated vesicle biogenesis	4	1,56E-02
Selenocompound metabolism	3	1,73E-02
Calnexin/calreticulin cycle	3	1,39E-02

“**ERO1A** together with **P4hb (PDI)** regulates the expression of MHC class I via oxidative folding” (Kukita et al. *J Immunol* 194, 4988–96 (2015))



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE


TIMO
Tumor Immunology
Meets Oncology

DGfI
Deutsche Gesellschaft
für Immunologie e.V.


DFG

MSA activates ERO1a



ERO1α:
DC₉₉AVKPC₉₉HSDEVPDGIK



ERO1α:
YSEEANRIEEC₁₃₀EQAER



PDI:
YLLVEFYAPWC₅₅GHC₅₈K



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE


TIMO
Tumor Immunology
Meets Oncology

DGfI
Deutsche Gesellschaft
für Immunologie e.V.


DFG

MSA activates ERO1a




ERO1α:
DC₉₉AVKPCHSDEVPDGIK



ERO1α:
YSEEANRIEEC₁₃₀EQAER




PDI:
YLLVEFYAPWC₅₅GHC₅₈K




MSA activates ERO1a





ERO1a:
DC₉₉AVKPCHSDEVPDGIK



ERO1a:
YSEANRIEEC₁₃₀EQAER



PDI:
YLLVEFYAPWC₅₅GHC₅₈K



Methylseleninic acid (MSA)


- ➔ modulation of the MHC class I surface expression in tumor cells by
 - ✓ enhanced expression of IFN- γ signaling components
 - ✓ an upregulation of APM components
 - ✓ modulation the activity status of proteins involved in oxidative folding of MHC class I molecules
- ➔ Manipulation of the cellular redox status with redox active selenocompounds might reverse the tumor immune escape
- ➔ Adding of redox active selenocompounds might enhance the efficacy of immunotherapies

➔ **Please visit Poster No. 460**



Acknowledgement

Seliger Lab



Khleif Lab

Prof. Dr. Samir Khleif
Dr. Shamim Ahmad
Dr. Vivek Verma
Dr. Seema Gupta
Dr. Pankaj Gaur



Falko Hochgräfe
Prof. Christopher Lillig
Manuela Gellert

Thank you for your
attention



Claudia Lennicke
Institute of Med. Immunology,
Halle, Germany

ADVANCING CANCER IMMUNOTHERAPY WORLDWIDE



DGfI
Deutsche Gesellschaft
für Immunologie e.V.

